Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:04:39 ON 28 APR 2005

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:04:48 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2005 HIGHEST RN 849400-77-7
DICTIONARY FILE UPDATES: 27 APR 2005 HIGHEST RN 849400-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10743954.str



chain nodes :
6 7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5
chain bonds :
6-7 7-8 7-9 8-10 10-11 11-12 11-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 6-7 7-8 7-9 8-10 10-11 11-12 11-13
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:05:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10758 TO ITERATE

9.3% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 208945 TO 221375
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:05:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 216529 TO ITERATE

100.0% PROCESSED 216529 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.03

L3 11 SEA SSS FUL L1

=> s l3 and caplus/lc
45717647 CAPLUS/LC
L4 9 L3 AND CAPLUS/LC

=> s l3 not l4
L5 2 L3 NOT L4

=> d l5 1-2

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 438018-46-3 REGISTRY
ED Entered STN: 10 Jul 2002
CN Glycine, N-[4-(5-phenyl-2-oxazolyl)benzoyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H14 N2 O4
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 300395-44-2 REGISTRY
ED Entered STN: 30 Oct 2000
CN Glycine, N-[4-(4,5-dihydro-5-oxo-2-oxazolyl)benzoyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H10 N2 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil chemcats
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	171.33	171.54

FILE 'CHEMCATS' ENTERED AT 14:07:30 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE LAST UPDATED 23 APRIL 2005 (20050423/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 8 million records. See HELP CONTENT and NEWS FILE for details.

=> s l5
L6 2 L5

=> d l6 1-2

L6 ANSWER 1 OF 2 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession No. (AN): 2003:124577 CHEMCATS
Catalog Name (CO): Ambinter Screening Library
Publication Date (PD): 1 Jan 2004
Order Number (ON): T0500-1291
Chemical Name (CN): Glycine, N-[4-(5-phenyl-2-oxazolyl)benzoyl]-
CAS Registry No. (RN): 438018-46-3
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L6 ANSWER 2 OF 2 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession No. (AN): 2000:988451 CHEMCATS
Catalog Name (CO): Heterocyclic Compounds Catalog (milligram quantities)
Publication Date (PD): 15 Mar 2005
Order Number (ON): 3461
Chemical Name (CN): Glycine, N-[4-(4,5-dihydro-5-oxo-2-oxazolyl)benzoyl]-
CAS Registry No. (RN): 300395-44-2
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.60	176.14

FILE 'CAPLUS' ENTERED AT 14:08:05 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2005 VOL 142 ISS 18
FILE LAST UPDATED: 27 Apr 2005 (20050427/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:04:39 ON 28 APR 2005)

FILE 'REGISTRY' ENTERED AT 14:04:48 ON 28 APR 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 11 S L1 FULL
L4 9 S L3 AND CAPLUS/LC
L5 2 S L3 NOT L4

FILE 'CHEMCATS' ENTERED AT 14:07:30 ON 28 APR 2005
L6 2 S L5

FILE 'CAPLUS' ENTERED AT 14:08:05 ON 28 APR 2005

=> s l4
L7 5 L4

=> d ibib abs hitstr 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:878167 CAPLUS
DOCUMENT NUMBER: 141:366227
TITLE: Preparation of imidazolidin-2-one and oxazolidin-2-one derivatives as glucagon receptor antagonists/inverse agonists
INVENTOR(S): Kurukulasuriya, Ravi; Link, James T.; Patel, Jyoti R.; Sorensen, Bryan K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004209928	A1	20041021	US 2003-743954		20031223
PRIORITY APPLN. INFO.:			US 2002-437132P	P	20021230

OTHER SOURCE(S): MARPAT 141:366227
GI



I

AB Compds. of formula (I) or pharmaceutically suitable salts, esters or prodrugs thereof, [wherein A = CO2H, tetrazole; B = H, F, OH, alkoxy, NRaRb (wherein Ra, Rb = H, alkyl, alkylcarbonyl, alkylsulfonyl alkoxyalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclesulfonyl); D = aryl, heteroaryl; E = (CH2)n; m, n = 0, 1, 2; V = C(Rc), N (wherein Rc = H, alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl); W = C(RdRe), (Rd)N, O, S, S(O), S(O)2; X = C(O), C(O)C(RfRg), C(RfRg)C(O), C(S), C(RfRg), C(RfRg)C(RiRj), C:N(Rj), S(O), S(O)2; Y = C(RkRm), (Rk)N, O, S, S(O), S(O)2; Z = a bond, C(RpRq), C(RpRq)C(RsRt); Rd, Re, Rf, Rg, Ri, Rj, Rk, Rm, Rp, Rq, Rs, Rt = H, alkyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, arylalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylalkoxy] are prepared These compds. are novel glucagon receptor antagonists or inverse agonists and are useful for treating (1) type 2 diabetes in a mammal, (2) symptoms related to type 1 or type 2 diabetes in a mammal wherein said symptoms are selected from the group consisting of hyperglycemia, hyperinsulinemia, inadequate glucose clearance, obesity, hyperlipidemia, lipid metabolism disorders and hypertension, and (3) diabetes or syndrome X in a mammal. Thus, 3-[4-[1-(4-tert-butylcyclohexylamino)-2-(tert-butyldimethylsilanyloxy)ethyl]benzoylamino]propionic acid Et ester underwent addition reaction with 4-(trifluoromethoxy)phenyl isocyanate in THF at ambient temperature for 12 h to give 3-[4-[1-[N-(4-tert-butylcyclohexyl)-N'-(4-trifluoromethoxyphenyl)ureido]-2-(tert-butyldimethylsilanyloxy)ethyl]be

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 780763-70-4 CAPLUS
CN β-Alanine, N-[4-[(2Z)-3-[4-(1,1-dimethylethyl)cyclohexyl]-2-[(4-phenoxyphenyl)imino]-4-oxazolidinyl]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 780763-71-5 CAPLUS
CN β-Alanine, N-[4-[(2Z)-2-([1,1'-biphenyl]-4-ylimino)-3-[4-(1,1-dimethylethyl)cyclohexyl]-4-oxazolidinyl]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

nzoylamino]propionic acid Et ester (II). Desilylation of II with Bu4NF in THF at 0° for 30 min gave 3-[4-[1-[N-(4-tert-Butylcyclohexyl)-N'-(4-trifluoromethoxyphenyl)ureido]-2-hydroxyethyl]benzoylamino]propionic acid Et ester which was cyclized by treatment with polymer supported triphenylphosphine (0.146 g, 0.44 mmol) followed by di-Et azodicarboxylate, sapon. with NaOH in aq. MeOH, and acidification with 1 N aq. HCl to give N-[4-[3-(4-tert-butylcyclohexyl)-2-oxo-1-[4-(trifluoromethoxy)phenyl]imidazolidin-4-yl]benzoyl]-β-alanine. The compds. I were found to inhibit glucagon-stimulated cAMP prodn. at a concn. of 20 μM a range of about 50 to .apprx.100%.

IT 780763-68-0P, N-[4-[(2Z)-3-(4-tert-Butylcyclohexyl)-2-[[4-(trifluoromethoxy)phenyl]imino]-1,3-oxazolidin-4-yl]benzoyl]-β-alanine 780763-69-1P, N-[4-[(2Z)-2-[(4-Bromophenyl)imino]-3-(4-tert-butylcyclohexyl)-1,3-oxazolidin-4-yl]benzoyl]-β-alanine 780763-70-4P, N-[4-[(2Z)-3-(4-tert-Butylcyclohexyl)-2-[(4-phenoxyphenyl)imino]-1,3-oxazolidin-4-yl]benzoyl]-β-alanine 780763-71-5P, N-[4-[(2Z)-2-(1,1'-Biphenyl-4-ylimino)-3-(4-tert-butylcyclohexyl)-1,3-oxazolidin-4-yl]benzoyl]-β-alanine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-one and oxazolidin-2-one derivs. as glucagon receptor antagonists/inverse agonists for treating type II diabetes or symptoms related to type 1 or 2 diabetes)

RN 780763-68-0 CAPLUS
CN β-Alanine, N-[4-[(2Z)-3-[4-(1,1-dimethylethyl)cyclohexyl]-2-[[4-(trifluoromethoxy)phenyl]imino]-4-oxazolidinyl]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 780763-69-1 CAPLUS
CN β-Alanine, N-[4-[(2Z)-2-[(4-bromophenyl)imino]-3-[4-(1,1-dimethylethyl)cyclohexyl]-4-oxazolidinyl]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:182874 CAPLUS
DOCUMENT NUMBER: 140:235742
TITLE: Preparation of quinazolinones as inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors.
INVENTOR(S): Haughan, Alan Findlay; Buckley, George Martin; Dyke, Hazel Joan; Hannah, Duncan Robert; Richard, Marianna Dilani; Sharpe, Andrew; Williams, Sophie Caroline
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018462	A1	20040304	WO 2003-GB3600	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2002-19638	A 20020823
			GB 2003-3866	A 20030220
			GB 2003-12773	A 20030604

OTHER SOURCE(S): MARPAT 140:235742
GI



I

AB Title compds. [I; X = O, S; R1 = aliphatic, cycloaliph., cycloalkylalkyl; R2 = (substituted) heteroaryl, cyano; R3 = (Alk1)mL1(Alk2)nR6; m, n, p, q = 0, 1; Alk1-Alk4 = (substituted) aliphatic, heteroaliph. chain; L1, L2 = bond, linker atom or group; R6 = H, (substituted) cycloaliph., heterocycloaliph., aryl, heteroaryl; R4 = (Alk3)pL2(Alk4)qR7; R7 = H, halo, cyano, (substituted) cycloaliph., heterocycloaliph., aryl, heteroaryl; R5 = H, (substituted) aliphatyl; and the salts, solvates, hydrates, tautomers, isomers or N-oxides thereof], were prepared Thus, 2-amino-4-methoxy-N-(2-morpholin-4-ylethyl)-5-oxazol-5-ylbenzamide (preparation given) was refluxed 6 h with MgSO4 and p-TsOH in acetone to give 16% 7-methoxy-2,2-dimethyl-3-(2-morpholin-4-ylethyl)-6-oxazol-5-yl-2,3-dihydro-

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1H-quinazolin-4-one. I inhibited IMPDH with IC50s 5 μM.
IT **667939-89-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)
RN 667939-89-1 CAPLUS
CN β-Alanine, N-[2-amino-4-methoxy-5-(5-oxazolyl)benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:134480 CAPLUS
DOCUMENT NUMBER: 138:369309
TITLE: Multifunctional coupling agents: Synthesis and model reactions
AUTHOR(S): Jakisch, L.; Komber, H.; Bohme, F.
CORPORATE SOURCE: Institute of Polymer Research Dresden e.V., Dresden, D-0169, Germany
SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (2003), 41(5), 655-667
CODEN: JPACEC; ISSN: 0887-624X
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB New multifunctional coupling agents with one 2-oxazoline group, one oxazinone group, and one allyl ether group were prepared It was shown by means of model reactions that under the conditions of reactive extrusion, the 2-oxazoline group and the oxazinone group reacted selectively with carboxylic groups and amino groups, resp. The allyl ether group remained unaffected under the reaction conditions chosen. As a model reaction, the conversion of the coupling agents with 11-aminoundecanoic acid resulted in the formation of an allyloxy-functionalized poly(ester amide). The reaction could be performed stepwise, in the course of which the reaction of the amino group proceeded at 110° in solution, whereas the reaction of the carboxylic group was performed in the melt at 220°. Furthermore, the utilization of the coupling agents for the preparation of telechelic poly(propylene glycol) with one oxazoline group and one allyl ether group on each chain end was described.
IT **522616-67-7P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and model reaction of multifunctional coupling agents)
RN 522616-67-7 CAPLUS
CN Undecanoic acid, 11-[[4-(4,5-dihydro-2-oxazolyl)-2-[[4-(2-propenyloxy)benzoyl]amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



IT **522616-68-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and model reaction of multifunctional coupling agents)
RN 522616-68-8 CAPLUS
CN Undecanoic acid, 11-[[4-(4,5-dihydro-2-oxazolyl)-2-[[4-(2-propenyloxy)benzoyl]amino]benzoyl]amino]-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 522616-67-7
CMF C31 H39 N3 O6

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:354566 CAPLUS
DOCUMENT NUMBER: 137:78886
TITLE: Efficient and General Synthesis of 5-[(Alkoxycarbonyl)methylene]-3-oxazolines by Palladium-Catalyzed Oxidative Carbonylation of Prop-2-ynylamides
AUTHOR(S): Bacchi, Alessia; Costa, Mirco; Gabriele, Bartolo; Pelizzi, Giancarlo; Salerno, Giuseppe
CORPORATE SOURCE: Dipartimento di Chimica Generale Analitica e Chimica Fisica, Universita di Parma, Parma, 43100, Italy
SOURCE: Journal of Organic Chemistry (2002), 67(13), 4450-4457
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:78886
AB A variety of prop-2-ynylamides have been carbonylated under oxidative conditions to give oxazolines, oxazolines with chelating groups, and bisoxazolines bearing an (alkoxycarbonyl)methylene chain at the 5 position in good yields. The cyclization-alkoxycarbonylation process was carried out in alc. media at 50-70° and under 24 bar pressure of 3:1 carbon monoxide/air in the presence of catalytic amts. of 10% Pd/C or PdI2 in conjunction with KI. Cyclization occurred by anti attack of an oxygen function on the palladium-coordinated triple bond, followed by stereospecific alkoxycarbonylation, strictly resulting in E-stereochem. The structures of representative oxazolines and bisoxazolines have been determined by X-ray diffraction anal.
IT **440365-24-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 5-[(alkoxycarbonyl)methylene]-3-oxazolines by palladium-catalyzed oxidative carbonylation of prop-2-ynylamides)
RN 440365-24-2 CAPLUS
CN 2-Butenedioic acid, 2-[1-[[4-[(5E)-4,5-dihydro-5-(2-methoxy-2-oxoethylidene)-4,4-dimethyl-2-oxazolyl]benzoyl]amino]-1-methylethyl]-, dimethyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1990:612686 CAPLUS
DOCUMENT NUMBER: 113:212686
TITLE: Peptide analogs as human immunodeficiency virus (HIV) protease inhibitors
INVENTOR(S): Hanko, Rudolf H.; Scangos, George A.; Yoo-Warren, Heeja; Ramabhadran, Triprayar V.; Paessens, Arnold; Henning, Rolf; Tamburini, Paul Perry; Hoppe, Dieter; Hansen, Jutta; Rabe, Klaus
PATENT ASSIGNEE(S): Molecular Therapeutics, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 361341	A2	19900404	EP 1989-117616	19890923
EP 361341	A3	19910703		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8904541	A	19900329	FI 1989-4541	19890926
AU 8942308	A1	19900816	AU 1989-42308	19890926
AU 633017	B2	19930121		
DK 8904760	A	19900329	DK 1989-4760	19890927
NO 8903834	A	19900329	NO 1989-3834	19890927
ZA 8907338	A	19900725	ZA 1989-7338	19890927
JP 02191243	A2	19900727	JP 1989-253683	19890928
PRIORITY APPLN. INFO.:			US 1988-250472 A	19880928
			US 1989-386194 A	19890801

OTHER SOURCE(S): MARPAT 113:212686
GI For diagram(s), see printed CA Issue.
AB AlkZnYmA2 [A1 = H, R1CO; R1 = OR2, NR2R3, CR2R3R4; R2, R3, R4 = (substituted) aliphatyl, aryl; k, n = 0, 1, k = 0 when Z = H; n = 0 when Y = H; Z = H, Ser, Thr, R1CO; Y = H, R5CO; R5 = R1, HNCHR9CO; R9 = (substituted) aliphatyl; A2 = E4E2QE1X, etc; E4 = H, Asn, R1CO; E2 = HNCH(CH2R6)CH(OH)CH2, HNCH(CH2R6)P(OH)(O), etc.; Q = 4-7-membered (hetero)cyclylene; E1 = CO; X = H, R1, HNCHR7R10; R6, R7 = (substituted) aliphatyl, aryl; R10 = H, COR1, CONHCHR9COR1], were prepared Thus, title compound I, prepared by solution phase methods, had an IC50 of 8 μM for inhibition of HIV protease.
IT 130372-03-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as HIV protease inhibitor)
RN 130372-03-1 CAPLUS
CN 3-Oxazolidinecarboxylic acid, 2,2-dimethyl-5-[2-[[[2-methyl-1-[(phenylmethoxy)carbonyl]butyl]amino]carbonyl]cyclopentyl]-4-(phenylmethyl)-, 1,1-dimethylethyl ester, [4S-[4α,5α[1S*,2S*(1R*,2R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.50	202.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

STN INTERNATIONAL LOGOFF AT 14:10:33 ON 28 APR 2005

L9 ANSWER 2 OF 4 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 136:134676 MARPAT
TITLE: Preparation of cyclic amine phenyl β3 adrenergic receptor agonists for treatment of metabolic disorders related to insulin resistance or hyperglycemia
INVENTOR(S): Hu, Baihua; Sum, Fuk-Wah; Malamas, Michael Sotirios
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006232	A1	20020124	WO 2001-US22387	20010716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002028835	A1	20020307	US 2001-903754	20010712
US 6525202	B2	20030225		
CA 2416245	AA	20020124	CA 2001-2416245	20010716
EP 1301482	A1	20030416	EP 2001-984234	20010716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012522	A	20030624	BR 2001-12522	20010716
JP 2004504299	T2	20040212	JP 2002-512136	20010716
US 2003144326	A1	20030731	US 2002-330576	20021227
PRIORITY APPLN. INFO.:			US 2000-218627P	20000717
			US 2001-903754	20010712
			WO 2001-US22387	20010716

GI



I



II

AB Title compds. I [wherein A = (hetero)aryl or heterocyclyl; X = OCH2, SCH2, or a bond; T1 = (CH2)m; T2 = (CH2)n; m = 1-3; n = 1-3; T = a bond,

(un)substituted alkyl or alkenyl, alkynyl, alkylthio, alkylamino, alkoxy(alkyl), alkylthioalkyl, acyl, or alkenylcarbonyl; R1, R2, and R3 = independently H, (cyclo)alkyl, OH, halo, CF3, alkoxy, benzyloxy, allyloxy, propargyloxy, acyloxy, CN, NO2, NH2, CONH2, (di)alkylamino, formamido, ureido, acylamino, alkylsulfonylamino, arylsulfonylamino, dialkyloxyphosphorylamino, dihydroxyphosphorylamino, alkoxycarbonyl, or (un)substituted aryl; R4 = H, alkyl, halo, OH, alkoxy, alkylthio, (alkyl)amino, carboxy, acyl, arylcarbonyl, alkoxycarbonyl, CONH2, alkylaminocarbonyl, alkylsulfonyl, or arylsulfonylamino; R5 = (un)substituted (di)oxoimidazolidinyl, (di)oxooxazolidinyl, (di)oxothiazolidinyl, dioxooxadiazolidinyl, tetrazolyl, oxopyrrolinyl, alkoxycarbonyl, aminocarbonyl, acyl, ureido, etc.; or a pharmaceutically acceptable salt thereof] were prepared by standard and combinatorial synthetic methods as β3 adrenergic receptor agonists. For example, acetic acid was added to a mixture of N-[5-[(1R)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide (preparation given), 2-[4-(4-oxo-1-piperidinyl)benzyl]-1,2,4-oxadiazolidine-3,5-dione, and DMF. Sodium triacetoxyborohydride was added and the mixture stirred at room temperature for 24 h to give (R)-I (71%). The latter bound to the β3 adrenergic receptor with EC50 of 20 μM, exhibited a maximal response activity equivalent to isoproterenol, and increased thermogenesis in β3 transgenic mice by 30 ± 8% compared to an increase of 16 ± 4% in β3 knockout mice. Thus, I are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension, frequent urination, and are particularly useful in the treatment or inhibition II diabetes.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 4 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 135:288773 MARPAT
TITLE: Preparation of Oxa(thia)zolidine derivative as anti-inflammatory agents
INVENTOR(S): Takagi, Masae; Ishimitsu, Keiichi; Nishibe, Tadayuki
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
[redacted]			WO 2001-JP2481	20010327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001044566	A5	20011008	AU 2001-44566	20010327
EP 1277743	A1	20030122	EP 2001-917503	20010327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002080368	A2	20020319	JP 2001-184538	20010619
US 2003199479	A1	20031023	US 2002-240075	20020925
[redacted]	B2	20040713		

US 2004220244	A1	20041104	US 2004-853829	20040526
PRIORITY APPLN. INFO.:			JP 2000-88078	20000328
			JP 2000-141395	20000515
			JP 2000-182811	20000619
			WO 2001-JP2481	20010327
			US 2002-240075	20020925

GI



AB Title compds. [I; X = S, O; R1 = CH3, H, CH2Cl, CH2F, CH3CH2, CH3(CH2)2; R2 - 4-CH3C6H4, 4-ClC6H4, C6H5, 2-thienyl, 2-naphthyl, 2-NO2C6H4, 4-CH3CO2C6H4, 4-CH3(CH2)3C6H4, 4-CH3OC6H4, 4-CF3C6H4, 4-CH3CH2C6H4, 2-pyridyl, 3-pyridyl; R3 = H, SO2N(CH3)2, SO2NHC6H4, CH3CH2ONHCO, 4-CH3O-3-NO2C6H3CH2, COCH3, COCH:CH2, CH2CH(C6H5)OCOCH3, CONHCH2CH3, CH3OCONHCS, 2-THPNHCO, 4-ClC6H4NHCO, 4-CF3OC6H4NHCO, cyclohexylaminocarbonyl, CH3OCONHCS; R = NH, NCN, NNO2, NCH3, NOCH2CH3, O, S, cyclohexylaminocarbonylimino, 4-CF3OC6H4N, C6H5N, (CH3)2NHCON] and stereoisomers are prepared as phospholipase A(2) inhibitors. Title compds. I or pharmacol. acceptable composites are used in medicinal compns. as the active ingredient of antiinflammatories. Thus, the title compound II was prepared and biol. tested.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 4 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	120:106987 MARPAT
TITLE:	Fungicidal oxazolidinones
INVENTOR(S):	Campbell, Carlton Lane; Gross, Charlene Marie; Sternberg, Jeffrey Arthur; Sun, King Mo
PATENT ASSIGNEE(S):	du Pont de Nemours, E. I., and Co., USA
SOURCE:	PCT Int. Appl., 131 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318016	A1	19930916	WO 1993-US2164	19930310
W: AU, BR, CA, FI, HU, JP, MG, NO, NZ, PL, RO, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9338006	A1	19931005	AU 1993-38006	19930310
EP 630370	A1	19941228	EP 1993-907384	19930310
R: DE, ES, FR, GB, IT				

PRIORITY APPLN. INFO.:	US 1992-849563	19920311
	WO 1993-US2164	19930310

GI



I



II



III

AB The title compds., 3-amino-4-oxazolidinones I (R1, R2 = alkyl, haloalkyl, etc.; R3 = Ph, pyridinyl, pyrimidinyl, etc.; R4 = hydrogen, Me, acetyl; W = oxygen, sulfur, amino) and their uses as agrochem. fungicides are claimed. An example compound, 5-(4-hydroxyphenyl)-5-methyl-3-(phenylamino)-2,4-oxazolidinedione (II) was prepared in several steps. Another example compound, 5-(2-fluoro-6-phenoxy-3-pyridyl)-5-methyl-3-(phenylamino)-2,4-oxazolidinedione (III) had fungicidal activity against Puccinia recondita, Phytophora infestans and Plasmopara viticola.

=>